Durcan L, et al. - Given that low complement represents an essential serological manifestation in SLE, researchers assessed cases with a history of, and that with persistently, low complement. They also carried out an investigation among those with positive antiphospholipid antibodies to assess thrombotic outcomes, because complement activation happens in the antiphospholipid antibody syndrome. A longitudinal SLE cohort was used. Organ manifestations, damage, C3, C4 and antiphospholipid antibodies were evaluated quarterly. As per findings, low C4 was identified as a weak marker in terms of the related clinical as well as serological manifestations. Renal involvement and poor renal outcomes were observed in relation to low C3. A history of both low C3 and C4 was identified to be linked with stroke in the presence of lupus anticoagulant or anticardiolipin antibodies, and low C4 with digital gangrene (with lupus anticoagulant).